A New Drug Used for Advanced Cancer
To identify the safety and tolerance of TQ-B3203.
Cancer
DRUG: TQ-B3203
The maximum tolerated dose(MTD), 21 days|dose-limiting toxicity(DLT), 21 days|Peak Plasma Concentration(Cmax), 21 days|Peak time（Tmax）, 21 days|Half life（t1/2）, 21 days|Area under the plasma concentration versus time curve (AUC), 21 days|Clearance（CL）, 21 days
Objective Response Rate(ORR), each 42 days up to intolerance the toxicity or progression disease (up to 24 months)
To identify the safety and tolerance of TQ-B3203.